1.	Phase II Randomized Study of Docetaxel With Versus Without Dimethylxanthenone Acetic Acid (AS1404) in Patients With Hormone-Refractory Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ANTISOMA-AS1404-203, WIRB-20050432, NCT00111618
2.	Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SAKK 15/08, SWS-SAKK-15-08, EUDRACT-2009-016960-34, EU-21001, NOVARTIS-CASA404ACCH01T, NCT01057342
3.	Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Phase: Phase II Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: Other Protocol IDs: GU09-144, NCT01071928
4.	Phase I Study of Dimethylxanthenone Acetic Acid in Patients with Solid Tumors Phase: Phase I Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: CRC-PHASE-I/II-PH1/048, EU-98065, NCT00003697
5.	An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC) Phase: Phase I Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CASA404A1101, NCT00674102